Glucagon-Like Peptide 1 – Page 5 – Talk Bio

Actionable Insights Powered by AI

Hims & Hers Super Bowl Ad Sparks Controversy Over Weight Loss Drug Marketing

7 months ago talkbio0Tagged Consumer Safety, Dosage Forms, Glucagon-Like Peptide 1, Hims & Hers, scrutiny, Super Bowl ad, Telemedicine, United States Food and Drug Administration, Weight-Loss Agents

Hims & Hers, Super Bowl ad, weight loss drugs, FDA scrutiny, compounded GLP-1 drugs, pharmaceutical advertising, telehealth, consumer safety

Eli Lilly’s Zepbound Surpasses $4.9 Billion in First Year Sales Despite Q4 Shortfall

7 months ago talkbio0Tagged Advice, earnings, Eli, Eli Lilly, Glucagon-Like Peptide 1, Mounjaro, Obesity, pharmaceutical revenue, Zepbound

Eli Lilly, Zepbound, obesity drug, Q4 2024 earnings, pharmaceutical revenue, GLP-1 medications, Mounjaro, 2025 guidance

GLP-1 Weight Loss Drugs Make Super Bowl Advertising Debut Amid Shifting Health Marketing Landscape

8 months ago talkbio0Tagged Epidemic, Glucagon-Like Peptide 1, Health care facility, Hims & Hers, Obesity, pharmaceutical marketing, Super Bowl ads, Weight-Loss Agents

GLP-1, Super Bowl ads, Hims & Hers, weight loss drugs, pharmaceutical marketing, healthcare advertising, obesity epidemic

Novo Nordisk Seeks FDA Restriction on Victoza Compounding Amid Ongoing GLP-1 Supply Issues

9 months ago talkbio0Tagged Glucagon-Like Peptide 1, liraglutide, Nordisk, pharmaceutical regulation, United States Food and Drug Administration, Victoza

Novo Nordisk, FDA, Victoza, liraglutide, compounding, GLP-1, supply issues, pharmaceutical regulation

GLP-1 Medications: Balancing Efficacy and Concerns Amidst Celebrity Endorsements and Rising Demand

9 months ago talkbio0Tagged agonists, aspects of adverse effects, Diabetes Mellitus, Non-Insulin-Dependent, Employer, Endorsements, Famous Persons, Financial cost, Glucagon-Like Peptide 1, Health Planning, Long-term Safety, Weight Loss

GLP-1 agonists, Weight loss, Type 2 diabetes, Celebrity endorsements, Side effects, Long-term safety, Cost implications, Employer health plans

Eli Lilly Intervenes in Lawsuit to Block Compounded Versions of Tirzepatide Following FDA’s Shortage Resolution

9 months ago talkbio0Tagged Eli, Eli Lilly, Glucagon-Like Peptide 1, Mounjaro, Pharmacy facility, shortage, United States Food and Drug Administration, Zepbound

Eli Lilly, tirzepatide, GLP-1 shortage, FDA, compounding pharmacies, lawsuit, Mounjaro, Zepbound

Eli Lilly’s Zepbound Receives FDA Approval as First Prescription Drug for Moderate-to-Severe Obstructive Sleep Apnea in Adults with Obesity

9 months ago talkbio0Tagged Approved, Glucagon-Like Peptide 1, Obesity, Sleep Apnea, Obstructive, tirzepatide, United States Food and Drug Administration, Zepbound

GLP-1, Obstructive Sleep Apnea (OSA), Obesity, Zepbound, Tirzepatide, FDA Approval, Sleep Disorder Treatment

FDA Reaffirms End of Tirzepatide Shortage, Impacting Compounders

9 months ago talkbio0Tagged Compounders, Drug Shortage, Eli, Eli Lilly, Glucagon-Like Peptide 1, Mounjaro, United States Food and Drug Administration, Zepbound

FDA, tirzepatide, GLP-1, drug shortage, compounders, Eli Lilly, Mounjaro, Zepbound

FDA Confirms Tirzepatide Availability, Compounders Express Concerns, While Semaglutide Shortage Persists

9 months ago talkbio0Tagged Availability of, Compounders, Dosage Forms, Drug Shortage, Glucagon-Like Peptide 1, semaglutide, United States Food and Drug Administration

FDA, tirzepatide, semaglutide, GLP-1 drug shortage, compounders, pharmaceutical availability

Novo Nordisk’s Vision for the Future of GLP-1 Therapies: Expanding Beyond Diabetes and Obesity

9 months ago talkbio0Tagged advancements, agonists, Chronic disease, Diabetes Mellitus, Non-Insulin-Dependent, Future, Glucagon-Like Peptide 1, Nordisk, Obesity, semaglutide

GLP-1 agonists, Novo Nordisk, Type 2 diabetes, Obesity, Future treatments, Chronic diseases, Semaglutide, Tirzepatide, Therapeutic advancements